Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) recieves FDA approval of VARUBI, an NK1 receptor antagonist for the prevention of CINV

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO

100%

Additional Information

Management Comment "VARUBI provide sustain protection from delayed nausea and vomiting for patients who are receiving emetogenic chemotherapy. And it’s administered with the single oral dose prior to initiation of chemotherapy.Importantly, use of VARUBI does not require oncologists to adjust the dose of dexamethasone or many other medicines that a patient maybe taken during their cancer therapy since it does induce or inhibit CYP3A4."-CEO Lonnie Moulder
http://seekingalpha....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 01, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Varubi, Cinv, Nausea And Vomiting, Emetogenic Chemotherapy